In new study, researchers show that genome sequencing provides more answers than traditional genetic testing.
With a more inclusive reference data set, scientists and doctors will be able to more easily spot clinically relevant genetic variants for all people.
One major obstacle to precision medicine for all? The cost of sequencing each person’s genome. New sequencing startups could change that.
While working to understand not only his own rare disease but also how the broader healthcare industry develops treatments for rare diseases as a whole, Onno Faber uncovered the building blocks of his new company.
In his latest book, clinical geneticist and biotech entrepreneur Dr. Phil Reilly chronicles centuries of medical progress that have contributed to recent breakthroughs in rare disease medicines, diagnostics, and clinical care. He says we're just...
New studies demonstrate that treating cancer based on its molecular vulnerabilities, rather than where it originated, could translate to better outcomes for patients